Skip to main content

Mueller Brian's Form 4 filing

Biomarin Pharmaceutical Inc (BMRN) · filed Nov 28, 2022

Accession no.
0001567619-22-020937
Filed
Nov 28, 2022
Trade date
Nov 23, 2022
Filing delay
5 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $531.1K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Mueller BrianCIK 0001514980Officer (EVP, Chief Financial Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 23, 2022Common StockSSaleDisposed−934$95.09−$88,814.0629,792Direct
Nov 23, 2022Common StockSSaleDisposed−945$99.50−$94,027.528,847Direct
Nov 23, 2022Common StockMOption exerciseAcquired+3,500$67.81+$237,33532,347Direct
Nov 23, 2022Common StockSSaleDisposed−3,500$99.50−$348,25028,847Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 23, 2022Common StockMOption exerciseDisposed−3,500$0.00$03,761Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)